522 related articles for article (PubMed ID: 10102000)
1. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.
Hogg RS; Yip B; Kully C; Craib KJ; O'Shaughnessy MV; Schechter MT; Montaner JS
CMAJ; 1999 Mar; 160(5):659-65. PubMed ID: 10102000
[TBL] [Abstract][Full Text] [Related]
2. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
3. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.
Hogg RS; Heath KV; Yip B; Craib KJ; O'Shaughnessy MV; Schechter MT; Montaner JS
JAMA; 1998 Feb; 279(6):450-4. PubMed ID: 9466638
[TBL] [Abstract][Full Text] [Related]
4. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine.
Justice AC; Stein DS; Fusco GP; Sherrill BH; Fusco JS; Danehower SC; Becker SL; Hansen NI; Graham NM;
J Clin Epidemiol; 2004 Jan; 57(1):89-97. PubMed ID: 15019015
[TBL] [Abstract][Full Text] [Related]
5. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
Olsen CH; Gatell J; Ledergerber B; Katlama C; Friis-Møller N; Weber J; Horban A; Staszewski S; Lundgren JD; Phillips AN;
AIDS; 2005 Feb; 19(3):319-30. PubMed ID: 15718843
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens. Triest Cohort Investigators.
Girard PM; Guiguet M; Bollens D; Goderel I; Meyohas MC; Lecomte I; Raguin G; Frottier J; Rozenbaum W; Jaillon P
Clin Infect Dis; 2000 Oct; 31(4):987-94. PubMed ID: 11049781
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
8. Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine.
Coplan PM; Cook JR; Carides GW; Heyse JF; Wu AW; Hammer SM; Nguyen BY; Meibohm AR; DiNubile MJ;
Clin Infect Dis; 2004 Aug; 39(3):426-33. PubMed ID: 15307012
[TBL] [Abstract][Full Text] [Related]
9. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F;
Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
11. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME
Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
[TBL] [Abstract][Full Text] [Related]
12. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.
Etard JF; Ndiaye I; Thierry-Mieg M; Guèye NF; Guèye PM; Lanièce I; Dieng AB; Diouf A; Laurent C; Mboup S; Sow PS; Delaporte E
AIDS; 2006 May; 20(8):1181-9. PubMed ID: 16691070
[TBL] [Abstract][Full Text] [Related]
13. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
[TBL] [Abstract][Full Text] [Related]
14. Update on HIV/AIDS in Thailand.
Ruxrungtham K; Phanuphak P
J Med Assoc Thai; 2001 Jun; 84 Suppl 1():S1-17. PubMed ID: 11529320
[TBL] [Abstract][Full Text] [Related]
15. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
16. Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.
Brumme ZL; Henrick BM; Brumme CJ; Hogg RS; Montaner JS; Harrigan PR
Antivir Ther; 2005; 10(7):849-53. PubMed ID: 16312181
[TBL] [Abstract][Full Text] [Related]
17. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
[TBL] [Abstract][Full Text] [Related]
18. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
[TBL] [Abstract][Full Text] [Related]
19. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire.
Seyler C; Anglaret X; Dakoury-Dogbo N; Messou E; Touré S; Danel C; Diakité N; Daudié A; Inwoley A; Maurice C; Tonwe-Gold B; Rouet F; N'Dri-Yoman T; Salamon R;
Antivir Ther; 2003 Oct; 8(5):385-93. PubMed ID: 14640385
[TBL] [Abstract][Full Text] [Related]
20. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]